ALFA Filings
Every announcement, straight from the exchange
Every Medplus Health Services earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.
Q2 FY27 revenue ₹2,037cr (+21.3% YoY), operating EBITDA ₹98cr (4.8% margin), reported PAT ₹56cr (+1% YoY). Store expansion continues; no explicit guidance given.
Medplus reported strong revenue growth but faced significant margin pressure from a lower private label mix and rising employee costs due to regulatory changes.
MedPlus reported Q1 FY27 revenue of ₹18,796M (+21.8% YoY) but saw Operating EBITDA decline 10.6% YoY to ₹651M. Strategy focuses on store network expansion, particularly franchisees.
MedPlus reported Q4 FY26 consolidated revenue of INR 18,644 million with a 5.8% EBITDA margin. Strategy shifts toward a franchisee model for faster, capital-efficient expansion.
Medplus delivered strong revenue growth while pivoting toward a franchise-led expansion model to optimize capital allocation. Management maintains a confident tone despite store closures and fluctuating private label contributions.
MedPlus FY26 revenue reached ₹68,925m, up 12.3% YoY. Strategy focuses on cluster-based expansion with 5,330 stores and increasing private label share.